CLINICAL ROLE -
Ryan Haumschild, PharmD, MS, MBA, leads a discussion surrounding relapsed/refractory multiple myeloma (MM).
EP. 1: Risk Stratification in Patients with Multiple Myeloma
EP. 2: Individualizing Treatment Strategies for Patients with RRMM
Ryan Haumschild, PharmD, MS, MBA, leads a panel surrounding individualized strategies for treating patients with relapse/refractory (RR) MM.
EP. 3: Economic Burden Associated with RRMM
A panel of experts explore burdens facing patients diagnosed with RRMM.
EP. 4: Unmet Needs in Treatment of Multiple Myeloma
Kathryn Maples, PharmD, BCOP, provides insights regarding unmet needs in treatment for relapsed/refractory multiple myeloma.
EP. 5: Treatment Landscape Surrounding Multiple Myeloma
A panel of experts navigate the treatment landscape in multiple myeloma.
EP. 6: Optimizing Multiple Myeloma Treatment With Anti-CD38 Agents
Medical experts emphasize anti-CD38 agent utilization for treatment of patients with multiple myeloma.
EP. 7: Considerations for Utilizing Anti-CD38 Drugs
Dr Haumschild leads a discussion surrounding key considerations when using anti-CD38 drugs.
EP. 8: Overview of IKEMA and CANDOR Trial
Experts discuss the results of the IKEMA and CANDOR trials.
EP. 9: Optimizing Multiple Myeloma Treatment with 4-Drug Regimens
4-drug treatment regimens could provide optimal care strategies for patients with multiple myeloma.
EP. 10: Developing Clinical Pathways for Multiple Myeloma
Key opinion leaders emphasize the critical role of effective clinical pathways for treatment in multiple myeloma.
EP. 11: Dosing Regimens Drive Total Cost of Care in Multiple Myeloma
Total cost of care for multiple myeloma can be significantly affected by selection of dosing regimen.
EP. 12: Monitoring and Managing Treatment Toxicity for Patients on Anti-CD38 Regimens
Toxicity management associated with anti-CD38 drugs is highlighted by a panel of medical experts.
EP. 13: Trajectory of Relapsed/Refractory Multiple Myeloma Treatment Landscape
In their closing thoughts, Mr Haumschild leads the panel in a discussion regarding treatments on the horizon for patients with relapsed/refractory multiple myeloma.
2 Clarke Drive Cranbury, NJ 08512